AML-MR Mutations Drive the Benefit of CPX-351 over 7+3 in the Pivotal Phase 3 AML Trial
Shimony S, Murdock H, Keating J, Reilly C, Tsai H, Gibson C, Faderl S, Wagner T, Dronamraju N, Lin T, Ritchie E, Prebet T, Cortes J, Uy G, Lancet J, Neuberg D, Stone R, Lindsley R. AML-MR Mutations Drive the Benefit of CPX-351 over 7+3 in the Pivotal Phase 3 AML Trial. Blood 2024, 144: 60-60. DOI: 10.1182/blood-2024-200413.Peer-Reviewed Original ResearchAcute myeloid leukemiaTherapy-related AMLGermline DDX41 mutationsCPX-351Platelet recovery timeTP53 mutationsOverall survivalDDX41 mutationsTreatment armsCR/CRi rateMedian OSS-AMLPrognosis of t-AMLTherapy-related acute myeloid leukemiaAnalyzed outcomesSecondary acute myeloid leukemiaAML classificationSubsets of acute myeloid leukemiaConcurrent TP53 mutationImproved overall survivalHistory of MDSDe novoPhase 3 trialFavorable treatment outcomesTargeted mutation analysisA post-hoc analysis of outcomes of patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) who received oral azacitidine (Oral-AZA) maintenance therapy in the QUAZAR AML-001 study.
Voso M, De Botton S, Pfeilstöcker M, Figuera Alvarez A, Wang K, L. See W, Ugidos Guerrero M, Lopes de Menezes D, Petrlik E, Prebet T, Roboz G. A post-hoc analysis of outcomes of patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) who received oral azacitidine (Oral-AZA) maintenance therapy in the QUAZAR AML-001 study. Journal Of Clinical Oncology 2024, 42: 6522-6522. DOI: 10.1200/jco.2024.42.16_suppl.6522.Peer-Reviewed Original ResearchRelapse-free survivalHematopoietic stem cell transplantationOral-AZAPoor-risk cytogeneticsAML-MRCOutcomes of patientsMedian OSOverall survivalTreatment armsMedian relapse-free survivalAnalysis of outcomes of patientsProlonged median OSMyelodysplasia-related changesStem cell transplantationPhase 3 studyKaplan-Meier methodAcute myeloid leukemiaEffective treatment optionYears of agePost hoc analysisOral azacitidinePlacebo QDImproved OSMRD negativitySecondary AML